Header: For years, one of the Grand Questions in genomics has been "in house versus send out." I asked Claude Opus 4.7 to write a book chapter on how the pro's and con's currently align.
As always with "AI Guest Column," the point is not the "answer" but to show us a checkpoint on how AI currently researches data and assembles an argument.
####
Will new landmark events, like the approval of the 500-gene ILMN TSO PMA platform at FDA, shape the insource-outsource questions? I asked Claude Opus 4.7, which came back with a 20 page computer-generated book chapter on the question.
####
https://drive.google.com/file/d/1XnT_8ofauxOjyq8WjgUwsSb5V328J-7A/view?usp=sharing
Summary
Precision oncology has advanced rapidly because genomic
testing has made cancer treatment increasingly targetable, measurable, and
data-driven. Yet the business landscape remains hard to predict: FDA approval,
strong reimbursement, and technical performance do not automatically translate
into broad adoption.
This AI-generated report (Opus 4.7) uses Illumina’s TruSight Oncology Comprehensive
assay as a test case for a larger industry question: whether distributed,
platform-based IVD kits — now reaching the scale of 500-gene comprehensive
genomic profiling — can shift oncology testing away from national reference
laboratories and back toward hospital and academic medical centers.
The analysis reviews the current market, the strategic
appeal of in-house CGP, and the barriers that may constrain adoption, including
local validation, uneven case volumes, oncologist preferences, EHR integration,
and the broader data ecosystems built by Foundation Medicine, Tempus, Caris,
and similar firms.
This report is intended to aid both investors and
policy-makers. It provides the reader
with both a market-facing review and a demonstration of how AI-generated
analysis can help frame the present state of a fast-moving field and explore
plausible paths for its evolution.
